Portola Pharmaceuticals Priced, Nasdaq: PTLA
Developing a blood thinner and a novel reversal agent for acutely ill patients.
Industry: Health Care
First Day Return: +4.5%
PTLA
Developing a blood thinner and a novel reversal agent for acutely ill patients.
| IPO Data | |
|---|---|
| IPO Date | 05/21/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $122 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | South San Francisco, CA, United States |
| Founded | 2003 |
| Employees at IPO | 57 |
| Website www.portola.com | |
IPO News for Portola Pharmaceuticals
Portola Pharmaceuticals (PTLA) Performance
